Free Practice Questions for Iran Pharmacy Ph.D. Entrance Exam

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card

100+ Questions

100% Free

Loading practice questions...

Exam Review

Key Facts: Iran Pharmacy Ph.D. Entrance Exam Exam

130

Total MCQs on the official unified national written examination booklet (دفترچه واحد)

Sanjesh Pezeshki Doctoral Entrance Regulations

-1/3

Negative marking penalty applied to incorrect answers on the written paper

Sanjesh Pezeshki Examination Rules

25%

Minimum standardized written score required to qualify for academic interviews (open quota, recent cycles)

Sanjesh Pezeshki doctoral pharmacy admission announcements

50 / 20 / 30

Composite selection weighting: 50% written test, 20% research/CV, 30% academic interview

Sanjesh Pezeshki Doctoral Admission Guide

Annual

National test administration conducted once per academic year across medical universities

Sanjesh Pezeshki Annual Assessment Calendar

The Iranian Pharmacy Ph.D. Entrance Examination is a competitive 130-question national entrance test administered in a single unified booklet by Sanjesh Pezeshki with one-third negative marking. Reaching the minimum standardized written-score threshold published in the year's registration guide, set at 25% of the total standardized written score in recent pharmacy cycles, is required to advance to academic interviews for doctoral pharmacy programmes.

Sample Iran Pharmacy Ph.D. Entrance Exam Practice Questions

Try these sample questions to review concepts for the Iran Pharmacy Ph.D. Entrance Exam exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1In colloidal drug delivery systems, the zeta potential (zeta) is widely measured to predict the physical dispersion stability of electrostatically stabilized nanoparticles. Which magnitude of zeta potential is generally considered the threshold indicating strong electrostatic repulsion sufficient to prevent spontaneous particle agglomeration and flocculation?

A.Between +5 mV and +15 mV

B.Between -10 mV and +10 mV

C.Exactly 0 mV (the isoelectric point)

D.Greater than +30 mV or more negative than -30 mV

Explanation: Zeta potential is the electric potential at the slipping (shear) plane of the electrical double layer surrounding a colloidal nanoparticle. According to DLVO (Derjaguin-Landau-Verwey-Overbeek) theory, electrostatic repulsion between particles must overcome attractive London-van der Waals forces to prevent aggregation. A zeta potential with an absolute magnitude greater than 30 mV (i.e., > +30 mV or < -30 mV) provides sufficient repulsive energy barrier to ensure high colloidal stability in suspension.

2In preformulation and physical pharmacy, which thermodynamic equation describes the quantitative relationship between the temperature dependence of a drug's saturated solubility and its enthalpy of solution (delta-H_sol)?

A.Noyes-Whitney equation

B.Van 't Hoff equation

C.Henderson-Hasselbalch equation

D.Arrhenius equation

Explanation: The Van 't Hoff equation: d(ln K_sp)/dT = delta-H_sol / (R * T^2) (or in integrated form: ln(S2 / S1) = - (delta-H_sol / R) * (1/T2 - 1/T1)) describes the change in saturated solubility (S) as a function of temperature (T). For an endothermic dissolution process (delta-H_sol > 0), drug solubility increases with increasing temperature.

3In the formulation of polymeric micelles for the solubilization of hydrophobic anticancer drugs, what physical concentration threshold of amphiphilic block copolymers (e.g., PEG-PLA, Pluronics) must be exceeded for spontaneous self-assembly of core-shell micellar structures to occur in aqueous solution?

A.Glass transition concentration

B.Cloud point temperature

C.Critical Micelle Concentration (CMC)

D.Lower critical solution concentration

Explanation: The Critical Micelle Concentration (CMC) is the minimum concentration of amphiphilic surfactant or copolymer molecules above which unimers spontaneously self-assemble into thermodynamic micelles. For polymeric block copolymers (such as PEG-b-PLA or PEG-b-PCL), the CMC is characteristically very low (often 10^-6 to 10^-7 M), which confers superior kinetic and thermodynamic stability against premature disassembly upon systemic intravenous dilution compared to low-molecular-weight surfactants.

4Which mathematical release model represents drug dissolution from planar pharmaceutical matrix systems where release is governed predominantly by pure Fickian diffusion through a non-eroding matrix, predicting cumulative drug release proportional to the square root of time (Q proportional to t^0.5)?

A.Higuchi equation

B.Zero-order release model

C.Hixson-Crowell cube-root model

D.Kopcha dual relaxation model

Explanation: The Higuchi model (developed by Takeru Higuchi in 1961) describes drug release from insoluble planar matrices where release is controlled by Fickian diffusion through the matrix pores: Q = [D * (2A - Cs) * Cs * t]^0.5 = K_H * t^0.5, where Q is cumulative drug released per unit area, D is diffusion coefficient, A is total drug per unit volume, and Cs is drug solubility in the release medium.

5In classical compartment pharmacokinetic modeling, how is the elimination half-life (t1/2) mathematically related to the apparent volume of distribution (Vd) and systemic clearance (CL)?

A.t1/2 = (CL * Vd) / 0.693

B.t1/2 = (0.693 * CL) / Vd

C.t1/2 = (0.693 * Vd) / CL

D.t1/2 = 0.693 / (CL * Vd)

Explanation: Elimination half-life is a secondary pharmacokinetic parameter derived from the two primary independent parameters: volume of distribution (Vd) and clearance (CL). Because the first-order elimination rate constant k = CL / Vd, and t1/2 = ln(2) / k = 0.693 / k, substituting k yields: t1/2 = (0.693 * Vd) / CL. Consequently, an increase in Vd prolongs half-life, whereas an increase in CL shortens half-life.

6In the accelerated stability testing of pharmaceuticals governed by the Arrhenius equation (k = A * e^(-Ea / RT)), plotting which parameters on the y-axis and x-axis produces a linear plot with a slope equal to -Ea / R?

A.log(k) on the y-axis versus T (in Kelvin) on the x-axis

B.k on the y-axis versus T (in Celsius) on the x-axis

C.ln(k) on the y-axis versus 1/T (in Kelvin) on the x-axis

D.1/k on the y-axis versus 1/T on the x-axis

Explanation: Taking the natural logarithm of the Arrhenius equation yields: ln(k) = ln(A) - (Ea / R) * (1/T). Plotting ln(k) on the y-axis versus the reciprocal of absolute temperature in Kelvin (1/T) on the x-axis produces a straight line where the slope is -Ea / R and the y-intercept is ln(A). This allows extrapolation of degraded drug reaction rate constants at 25 °C (room temperature) from elevated temperatures (40 °C, 50 °C, 60 °C).

7Which biodegradable synthetic copolymer, approved by regulatory agencies worldwide, degrades in vivo via non-enzymatic hydrolytic ester cleavage into endogenous lactic acid and glycolic acid, making it widely utilized for sustained-release microspheres and implants (e.g., Lupron Depot)?

A.Poly(methyl methacrylate) (PMMA)

B.Polyethylene glycol (PEG)

C.Poly(lactic-co-glycolic acid) (PLGA)

D.Polyvinyl chloride (PVC)

Explanation: Poly(lactic-co-glycolic acid) (PLGA) is a biocompatible and biodegradable copolymer composed of lactic acid and glycolic acid monomers linked by ester bonds. In the presence of aqueous biological fluids, PLGA undergoes hydrolytic degradation into lactic acid (which enters the Krebs cycle) and glycolic acid (which is excreted or converted to glycine). Degradation rate and drug release kinetics can be tuned from weeks to months by altering the lactide-to-glycolide ratio and polymer molecular weight.

8In the design of clinical trials, which phase is primarily conducted in a small cohort (20 to 100) of healthy human volunteers to evaluate safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD)?

A.Phase III clinical trial

B.Phase II clinical trial

C.Phase I clinical trial

D.Phase IV post-marketing surveillance

Explanation: Phase I clinical trials represent the first-in-human testing of an investigational new drug (IND). They are conducted in a small group (20-100) of healthy human volunteers (or patients with advanced terminal cancer for cytotoxic therapies) to assess pharmacokinetics, ADME properties, safety profiles, adverse event thresholds, and the maximum tolerated dose (MTD) to establish a safe dose range for subsequent studies.

9A 56-year-old male with an acute ST-elevation myocardial infarction undergoes successful primary PCI. In post-infarction management, which drug class is indicated in all patients with reduced left ventricular systolic function (LVEF <= 40%) to attenuate adverse ventricular remodeling and reduce long-term cardiovascular mortality?

A.Non-dihydropyridine calcium channel blockers

B.Angiotensin-converting enzyme (ACE) inhibitors (or ARBs)

C.Class Ic antiarrhythmics (e.g., flecainide)

D.Direct oral factor Xa inhibitors at full therapeutic doses

Explanation: ACE inhibitors (e.g., ramipril, enalapril, lisinopril) or ARBs initiated within the first 24 to 48 hours post-MI in patients with left ventricular systolic dysfunction (LVEF <= 40%) suppress systemic and tissue angiotensin II and aldosterone production. This reduces ventricular wall stress, prevents progressive post-infarction chamber dilation and fibrosis (adverse remodeling), and significantly reduces the development of heart failure and all-cause mortality (proven in SAVE, AIRE, and TRACE trials).

10In the treatment of severe status epilepticus in the emergency department, what is the guideline-recommended initial first-line pharmacological therapy to terminate active seizures rapidly?

A.Oral Ethosuximide syrup

B.Oral Carbamazepine suspension

C.Intravenous Phenobarbital maintenance infusion

D.Intravenous Lorazepam (or intramuscular Midazolam)

Explanation: According to the American Epilepsy Society (AES) and international status epilepticus guidelines, intravenous lorazepam (0.1 mg/kg, typically 4 mg IV) or intramuscular midazolam (10 mg IM for adults >40 kg) is the first-line emergent treatment of choice. Benzodiazepines are potent positive allosteric modulators of GABA-A receptors, rapidly terminating continuous epileptic seizure activity within 2 to 5 minutes.

About the Iran Pharmacy Ph.D. Entrance Exam Exam

The Iranian Pharmacy Ph.D. Entrance Examination (آزمون دکتری تخصصی و پژوهشی رشته‌های داروسازی) is the competitive national entrance examination administered by the National Center for Health Assessment (مرکز سنجش آموزش پزشکی - Sanjesh Pezeshki) for Pharm.D. and master's degree graduates seeking admission into Doctor of Philosophy (Ph.D.) and advanced clinical residency disciplines at accredited medical universities across Iran. Programs include Clinical Pharmacy, Pharmaceutics, Medicinal Chemistry, Pharmacology & Toxicology, Pharmacognosy, Pharmaceutical Biotechnology, Nanotechnology, Nuclear Pharmacy, and Quality Control. All disciplines sit for a common, unified national examination booklet (دفترچه واحد) containing 130 multiple-choice questions. The specialist section comprises 100 questions divided into Pharmaceutics (25), Clinical Pharmacy (25), Pharmacology & Toxicology (25), Medicinal Chemistry (15), and Pharmacognosy (10), alongside 30 English-language proficiency items. One-third negative marking applies. Final admission combines the written examination (50%), academic/research portfolio (20%), and structured university interviews (30%). This question bank is an independent English-language MCQ study adaptation authored by OpenExamPrep. It focuses on the five specialist pharmaceutical disciplines with 100 rigorous, research-depth questions emphasizing mechanism, physical formulation science, clinical kinetics, and chemical analysis. It is an educational study aid and is neither an official translation nor affiliated with Sanjesh Pezeshki.

Exam sponsor: National Center for Health Assessment / Sanjesh Pezeshki (مرکز سنجش آموزش پزشکی). The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The national doctoral entrance examination is held annually in a single nationwide administration by the National Center for Health Assessment (مرکز سنجش آموزش پزشکی - Sanjesh Pezeshki). Under revised regulations, all general aptitude items (استعداد تحصیلی) have been abolished, and the examination is delivered in a single unified booklet (دفترچه واحد) consisting of 130 multiple-choice questions: 100 questions covering the five core pharmaceutical subjects and 30 questions covering general and specialized English. Standard one-third negative marking applies to all items. Admissions are weighted across the written examination (50%), educational and research credentials (20%), and the oral academic interview / scientific assessment (30%).

Time Limit

Timed single session per Sanjesh Pezeshki guidelines

Passing Score

Minimum 25% of the total standardized written score (open quota) to qualify for the interview stage; confirm the current threshold in the year's registration guide

Exam / Certification Fees

Set annually by the Ministry of Health and Medical Education, payable online via sanjeshp.ir during official registration

Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Official sources

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

25%

Pharmaceutics & Advanced Drug Delivery (فارماسیوتیکس)

Physical pharmacy, preformulation science, advanced drug delivery systems (liposomes, nanoparticles, polymeric micelles), biopharmaceutics, compartmental pharmacokinetics, non-compartmental analysis, and formulation stabilization (25 official questions).

25%

Clinical Pharmacy & Advanced Therapeutics (داروسازی بالینی)

Evidence-based clinical pharmacotherapy, critical care pharmacology, clinical trial design, therapeutic drug monitoring, individualized dosing regimens in organ dysfunction, and pharmacoeconomics (25 official questions).

25%

Pharmacology & Cellular Toxicology (فارماکولوژی و سم‌شناسی)

Receptor theory and signal transduction, molecular pharmacology, autonomic and central neuropharmacology, cardiovascular and cancer pharmacology, mechanisms of toxicity, and cellular toxicokinetics (25 official questions).

15%

Medicinal Chemistry & Molecular Modeling (شیمی دارویی)

Drug discovery and lead optimization, quantitative structure-activity relationships (QSAR), computer-aided drug design, synthetic pathways of therapeutic agents, and spectroscopic structural analysis (15 official questions).

10%

Pharmacognosy & Natural Product Chemistry (فارماکوگنوزی)

Biosynthetic pathways of secondary metabolites, isolation and purification techniques (chromatography, HPLC, LC-MS), structural elucidation of phytoconstituents, and bioassay-guided fractionation (10 official questions).

Preparing for the Iran Pharmacy Ph.D. Entrance Exam Exam

What You Need to Know

Passing score: Minimum 25% of the total standardized written score (open quota) to qualify for the interview stage; confirm the current threshold in the year's registration guide
Assessment: The national doctoral entrance examination is held annually in a single nationwide administration by the National Center for Health Assessment (مرکز سنجش آموزش پزشکی - Sanjesh Pezeshki). Under revised regulations, all general aptitude items (استعداد تحصیلی) have been abolished, and the examination is delivered in a single unified booklet (دفترچه واحد) consisting of 130 multiple-choice questions: 100 questions covering the five core pharmaceutical subjects and 30 questions covering general and specialized English. Standard one-third negative marking applies to all items. Admissions are weighted across the written examination (50%), educational and research credentials (20%), and the oral academic interview / scientific assessment (30%).
Time limit: Timed single session per Sanjesh Pezeshki guidelines
Exam / certification fees: Set annually by the Ministry of Health and Medical Education, payable online via sanjeshp.ir during official registration Official sources

Using Our Practice Resources

Work through all 100 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

Iran Pharmacy Ph.D. Entrance Exam: Suggested Study Strategy

1Master the high-weight triad: Pharmaceutics, Clinical Pharmacy, and Pharmacology & Toxicology each account for 25 questions in the official outline (75% of the specialist core). Focus intensively on advanced formulation kinetics, clinical pharmacotherapy in complex patients, and molecular receptor mechanisms.

2Account for negative marking: Because each incorrect answer carries a one-third penalty, guess only when you can confidently eliminate at least two distractors. Avoid random guessing on completely unfamiliar items.

3Focus on research-level depth: Unlike the undergraduate Pharm.D. exit exam, Ph.D. questions test deep mechanistic principles, including non-compartmental pharmacokinetic parameters, QSAR descriptors, spectroscopic data interpretation, and chromatographic isolation workflows.

4Understand discipline-specific coefficients: While the written booklet is identical for all disciplines, universities apply different subject coefficients (ضرایب) depending on your target specialty. Ensure top scores in your primary specialty field.

5Prepare for the multi-stage evaluation: Attaining a top written score is essential to secure an invitation to the academic interview (مصاحبه علمی), which evaluates research methodology, thesis defense quality, and scientific publications.

Frequently Asked Questions

What is the Iranian Pharmacy Ph.D. Entrance Examination?

The Pharmacy Ph.D. Entrance Examination (آزمون دکتری تخصصی و پژوهشی رشته‌های داروسازی) is the national competitive entrance examination conducted by Sanjesh Pezeshki under the Ministry of Health. It selects Pharm.D. and qualified master's degree holders for specialized doctoral and clinical pharmacy Ph.D. programs across Iranian medical sciences universities.

What is the structure of the exam and the official booklet?

The examination is administered as a single unified booklet (دفترچه واحد) containing 130 multiple-choice questions: 25 in Pharmaceutics, 25 in Clinical Pharmacy, 25 in Pharmacology & Toxicology, 15 in Medicinal Chemistry, 10 in Pharmacognosy, and 30 in English language. General aptitude (استعداد تحصیلی) has been completely removed.

Does negative marking apply to the Pharmacy Ph.D. Entrance Exam?

Yes. In accordance with Sanjesh Pezeshki postgraduate entrance regulations, standard negative marking applies: each correct answer receives +3 points, while each incorrect answer receives -1 point (a penalty of one-third of a mark per incorrect response). Unanswered questions receive 0 points.

How are final admissions decisions determined?

Final admission is based on a composite score: the nationwide written examination accounts for 50%, the applicant's educational, scientific, and research portfolio accounts for 20%, and the academic interview / oral evaluation accounts for 30%. Candidates must reach the minimum standardized written-score threshold published in the year's registration guide to qualify for interviews; recent pharmacy cycles set this at 25% of the total standardized written score for the open quota.

Why does this OpenExamPrep bank contain 100 questions instead of 130?

The official examination includes 30 English-language proficiency items that cannot be meaningfully represented in an English-language study adaptation. This question bank reallocates that weighting proportionally across the five specialist pharmaceutical science disciplines (100 questions total) to provide maximum high-yield scientific practice.

Is this OpenExamPrep question bank an official Sanjesh Pezeshki product?

No. This question bank is an independent English-language MCQ study adaptation authored by OpenExamPrep for postgraduate exam preparation. The official Iranian examination is administered in Persian by Sanjesh Pezeshki, and OpenExamPrep is not affiliated with or endorsed by Sanjesh Pezeshki or the Iranian Ministry of Health.